NeuroPace Reports First Quarter 2021 Financial Results and Provides 2021 Financial Guidance
Neuropace, Inc. (NPCE)
Company Research
Source: GlobeNewswire
MOUNTAIN VIEW, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ended March 31, 2021. Recent Highlights Total revenue of $11.2 million for the first quarter of 2021, representing a 12% increase over the comparable prior year period in 2020Initial implant revenue of $8.1 million for the first quarter of 2021, representing a 23% increase over the prior year periodCompleted an initial public offering of 6.9 million shares, raising approximately $105 million in net proceedsIssues 2021 total revenue guidance of approximately $47 million, representing 14% growth compared to 2020 “We are pleased with our quarterly results and continue to take a measured approach in the early stages of the COVID-19 recovery,” said Mike Favet, Chief Executive Office of NeuroPace. “In addition,
Show less
Read more
Impact Snapshot
Event Time:
NPCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NPCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NPCE alerts
High impacting Neuropace, Inc. news events
Weekly update
A roundup of the hottest topics
NPCE
News
- NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024GlobeNewswire
- NeuroPace to Present at the Needham 23rd Annual Healthcare ConferenceGlobeNewswire
- Revamp Medical Announces Appointment of Mike Favet as CEO [Yahoo! Finance]Yahoo! Finance
- NeuroPace, Inc. (NASDAQ: NPCE) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $16.00.MarketBeat
NPCE
Earnings
- 3/5/24 - Beat
NPCE
Sec Filings
- 4/23/24 - Form 4
- 4/22/24 - Form ARS
- 4/22/24 - Form DEFA14A
- NPCE's page on the SEC website